IL296736B2 - SIGLEC15-binding antibodies and their uses - Google Patents

SIGLEC15-binding antibodies and their uses

Info

Publication number
IL296736B2
IL296736B2 IL296736A IL29673622A IL296736B2 IL 296736 B2 IL296736 B2 IL 296736B2 IL 296736 A IL296736 A IL 296736A IL 29673622 A IL29673622 A IL 29673622A IL 296736 B2 IL296736 B2 IL 296736B2
Authority
IL
Israel
Prior art keywords
antibody
siglec15
variable region
chain variable
seq
Prior art date
Application number
IL296736A
Other languages
English (en)
Hebrew (he)
Other versions
IL296736A (en
IL296736B1 (en
Original Assignee
Biosion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosion Inc filed Critical Biosion Inc
Publication of IL296736A publication Critical patent/IL296736A/en
Publication of IL296736B1 publication Critical patent/IL296736B1/en
Publication of IL296736B2 publication Critical patent/IL296736B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL296736A 2020-03-27 2021-03-26 SIGLEC15-binding antibodies and their uses IL296736B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof

Publications (3)

Publication Number Publication Date
IL296736A IL296736A (en) 2022-11-01
IL296736B1 IL296736B1 (en) 2024-12-01
IL296736B2 true IL296736B2 (en) 2025-04-01

Family

ID=77891322

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296736A IL296736B2 (en) 2020-03-27 2021-03-26 SIGLEC15-binding antibodies and their uses

Country Status (12)

Country Link
US (2) US11739147B2 (enExample)
EP (1) EP4126938A4 (enExample)
JP (2) JP7364315B2 (enExample)
KR (1) KR102651263B1 (enExample)
CN (1) CN115348970B (enExample)
AU (2) AU2021240769B2 (enExample)
BR (1) BR112022019129A2 (enExample)
IL (1) IL296736B2 (enExample)
MX (1) MX2022011951A (enExample)
PH (1) PH12022552520A1 (enExample)
SA (1) SA522440646B1 (enExample)
WO (1) WO2021190622A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022552520A1 (en) * 2020-03-27 2023-01-04 Biosion Inc Antibodies binding siglec15 and uses thereof
TW202330617A (zh) * 2021-11-25 2023-08-01 大陸商正大天晴藥業集團股份有限公司 抗Siglec-15抗體及其應用
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
KR20250023399A (ko) * 2022-06-13 2025-02-18 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-siglec15 항체 및 이의 용도
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
MX2013003828A (es) * 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
CA2848074A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
BR112014024267A8 (pt) * 2012-03-30 2017-07-25 Daiichi Sankyo Co Ltd anticorpo ou um fragmento de ligação de antígeno do anticorpo, composição farmacêutica, usos de pelo menos um dos anticorpos ou fragmentos de ligação de antígeno e de uma composição, polinucleotídeo, vetor, e, célula hospedeira transformada
HK1210192A1 (en) * 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP3157562A4 (en) * 2014-06-18 2017-12-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
AU2016354100B2 (en) 2015-11-10 2023-11-30 Yale University Compositions and methods for treating autoimmune diseases and cancers
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
PH12022552520A1 (en) * 2020-03-27 2023-01-04 Biosion Inc Antibodies binding siglec15 and uses thereof

Also Published As

Publication number Publication date
US20230106715A1 (en) 2023-04-06
AU2021240769A1 (en) 2022-10-20
JP7364315B2 (ja) 2023-10-18
CA3173201A1 (en) 2021-09-30
KR20220158696A (ko) 2022-12-01
CN115348970B (zh) 2023-11-14
EP4126938A4 (en) 2024-04-10
JP7827951B2 (ja) 2026-03-11
JP2023518153A (ja) 2023-04-28
JP2024016024A (ja) 2024-02-06
US11739147B2 (en) 2023-08-29
AU2023203397A1 (en) 2023-06-29
AU2021240769B2 (en) 2023-04-06
NZ792658A (en) 2024-07-05
CN115348970A (zh) 2022-11-15
US20240002508A1 (en) 2024-01-04
IL296736A (en) 2022-11-01
KR102651263B1 (ko) 2024-03-25
SA522440646B1 (ar) 2024-08-29
EP4126938A1 (en) 2023-02-08
PH12022552520A1 (en) 2023-01-04
WO2021190622A1 (en) 2021-09-30
MX2022011951A (es) 2023-03-06
BR112022019129A2 (pt) 2022-12-06
IL296736B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20230055711A1 (en) Antibodies binding bcma and uses thereof
WO2021043221A1 (en) Antibodies binding tslp and uses thereof
US11739147B2 (en) Antibodies binding Siglec15 and uses thereof
US20230105029A1 (en) Antibodies binding il4r and uses thereof
US11136394B2 (en) Antibody binding PD-1 and use thereof
US12503517B2 (en) Antibodies binding CD40 and uses thereof
US20250250355A1 (en) Antibodies targeting sirp-alpha and uses thereof
US20200332017A1 (en) Antibodies or antigen-binding portions binding cd40 and uses thereof
US12559565B2 (en) Antibodies binding CTLA4 and uses thereof
AU2021330087B2 (en) PD-1 binding antibodies and uses thereof
WO2021136323A1 (en) Antibodies binding bcma and uses thereof
CA3173201C (en) Antibodies binding siglec15 and uses thereof
US20230034768A1 (en) Antibodies binding rankl and uses thereof
US20230167182A1 (en) Antibodies binding il6r and uses thereof